Introduction
Relaxin stimulation of growth and remodelling of reproductive tissues, including the uterus and cervix, is well established. In pigs, the uterotrophic effects of relaxin include increases in uterine size, dry mass, protein and DNA content and are observed after the administration of relaxin to prepubertal (Hall et al, 1990) or ovariectomized, prepubertal gilts (Hall et al., 1992) . In addition, exogenous relaxin increases uterine size during early pregnancy in gilts (Galvin et al., 1991) . These uterotrophic effects of relaxin are accompanied by a change in the uterine connective tissue matrix in response to relaxin (Hall et al., 1992) . Relaxin also promotes the growth and softening of the cervix (Kertiles and Anderson, 1979) , which is accompanied by a reduction in cervical collagen concentrations (O'Day et al., 1991; Hall and Anthony, 1993 (Too et al., 1986) . Similarly, in human amnion-chorion cells (Koay et al., 1986) , human fetal membrane explants (Qin et al., 1997) and rat granulosa cells (Too et al., 1984) , relaxin increases collagenase and PA secretion in vitro.
Urokinase-type (uPA) (Mullins et al., 1980) . Similarly, human uterine tissue has high PA activity during the proliferative phase of the menstrual cycle (Shaw et al., 1980) . In rats, increased PA activity in uterine fluid (Peltz et al., 1983) Uterine flushes
The secreted uPA activity in uterine flush samples from relaxin-treated pigs was fivefold greater (P < 0.05) than it was in control pigs (Fig la) . This stimulation of uPA activity in relaxin-treated animals was associated with an increase in immunoreactive uPA protein (Fig lb) . Western While uPA activity in the uterine flushes was increased by relaxin administration, the amount of secreted tPA activity in these samples was similar in both the relaxin-treated and control animals (Fig lc) . Baseline tPA activity in the uterine flush samples of control animals (Fig lc) was about fivefold higher (P < 0.05) than uPA activity in controls (Fig la) . Western blot analysis using an antibody to detect tPA protein showed the presence of a 72 and 78 kDa form of the protein in samples from both control and relaxin-treated pigs. Whereas tPA activity in the uterine flush samples was insensitive to relaxin treatment, there was a trend toward higher expression of the 72 kDa tPA band in two of the three relaxin-treated animals (Fig Id) , although this trend was not significant (P = 0.1). There was also no effect of relaxin administration in vivo on the intensity of the 78 kDa band when compared with that of control animals. Acidification of the uterine flush samples to remove putative acid-labile inhibitors of PA did not alter either uPA or tPA activity (data not shown).
Uterine and cervical extracts
When uterine tissue was analysed to measure cellassociated PA, the data showed no effect of relaxin treatment in vivo on either uPA activity (Fig. 2a) or uPA protein (Fig. 2b) . In addition to the 54 and 31 kDa forms of uPA observed in uterine flushes, the uterine tissue also expressed a 48 and 40 kDa protein that crossreacted with the uPA antibody. Analysis of uterine tissue showed no differences in tPA activity (Fig. 2c) or tPA protein (Fig. 2d) in response to relaxin. However, within uterine tissue, the amount of cellassociated tPA activity (Fig. 2c) was approximately five times greater (P < 0.05) than the amount of uPA activity (Fig. 2a) .
Since the effects of relaxin on cervical PA were similar in Fig. 1 (Fig. 3) . As with uterine tissue, there was no effect of relaxin treatment in vivo on cell-associated uPA activity (Fig 3a) or uPA protein (Fig   3b) in cervical tissue. However, tPA activity in the cervical extracts from relaxin-treated animals was reduced 2.5-fold (P < 0.05) when compared with tPA activity in controls.
However, the decrease in cervical tPA activity in response to relaxin was not correlated with a decrease in immunoreactive tPA protein (Fig. 3d) (Reich et al, 1985) , mammary gland involution (Ossowski et al., 1979) and implantation (Strickland and Richards, 1992 (Qin et al., 1997) . These data support a role for relaxin in the tissue remodelling involved in fetal membrane rupture. In the ovary, transforming growth factor increases granulosa cell uPA activity which is accompanied by an increase in DNA synthesis (Lafrance et al., 1993) . Similarly, insulin-like growth factor I (IGF-I) stimulates intrafollicular ovarian PA activity, and this increase in PA activity is significantly correlated with growth (Yoshimura et al., 1996) . Relaxin increases pig granulosa cell IGF-I secretion, and neutralization of IGF-I activity inhibits relaxin-induced granulosa cell growth in vitro (Ohleth and Bagnell, 1995) . In addition, the uterotrophic effects of relaxin in the prepubertal pig model used in the present study involve increases in IGF-I, IGF-II and IGFBPs (Ohleth et al, 1997) . Whether the effects of relaxin on PA activity in the uterus and cervix are mediated indirectly through changes in IGF secretion and availability or directly through interaction with relaxin receptors is unknown.
Net proteolytic activity mediated by the PA system involves regulation by specific PA inhibitors (PAI; Andreasen et al., 1990) . For example, acid-labile PA inhibitors have been reported to be present in secretions, such as amniotic fluid (Koay et al, 1986) and follicular fluid (Beers, 1975 
1990
). In addition, progesterone induces uterine secretion of a low molecular weight, acid-resistant plasmin inhibitor in pigs, which increases in response to oestrogen and differs from other pig protease inhibitors found in serum (Mullins et al., 1980; Fazleabas et al., 1982 Fazleabas et al., , 1983 . It has been suggested that this uterine-specific inhibitor may have a role in the unique, non-invasive nature of placentation in pigs as well as in preventing the premature destruction of uterine secretory proteins on which the conceptus relies (Fazleabas et al, 1982) .
However, the prepubertal pigs used in this study had negligible steroid hormone concentrations and, thus, were not expected to have high concentrations of progesteroneinduced, acid-resistant inhibitors of PA activity. There is evidence for the regulation of both PAI-1 and PAI-2 production by hormones and growth factors (Andreasen et al., 1990 (Casslén et al., 1986; Koh et al., 1992) and correspond to the two active forms of uPA (Saksela, 1985) . The However, the methods used to extract PA from tissues were those described by Shimada et al. (1985) , who reported significant changes in cell-associated PA activity during involution of the uterus. Given the importance of uPA in extracellular matrix degradation, the observation that relaxin promotes uterine secretion of uPA, rather than intracellular storage supports the idea that relaxin facilitates uterine growth and remodelling by increasing extracellular proteolysis.
In the uterus, neither cell-associated nor secreted tPA was influenced by relaxin treatment. This is in agreement with studies by Casslén et al. (1986) who reported an increase in uPA secretion from expiants of proliferative phase human endometrium in response to oestradiol, with little or no effect on tPA secretion. The fact that uPA, and not tPA, activity increased in the uterine flushings in response to relaxin may reflect the function of these enzymes. While tPA is associated with fibrinolysis and dissolution of blood clots, uPA appears to be more important in the extracellular matrix degradation critical for tissue remodelling (Littlefield, 1991 (Kirchheimer et al., 1987 
